Enanta Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Enanta Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Sep 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-5.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 55% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 24%
Sales fell 24% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-24% / -25%In 3 years sales changed by -24% while total assets changed by -25%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
-6.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 57% of Healthcare companies in United States.
Cash Cushion Ratio
+39%Cash, after subtracting all debt, equals 39% of its market value (net cash).
Higher than 73% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Enanta Pharmaceuticals, Inc. made a loss over the last year. Enanta Pharmaceuticals, Inc. owes $0.66 for every $1 it owns. Enanta Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossEnanta Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.35The share price is 3.35 times Enanta Pharmaceuticals, Inc.'s book value per share, higher than 59% of Healthcare companies in United States.
Market cap
$338 MThe total market value of all of Enanta Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$101 MWhat Enanta Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.47Net worth divided by the number of shares. The share price of $11.62 is 3.3 times this, which is the P/B above.
Return on equity (ROE)
-70.1%Enanta Pharmaceuticals, Inc. lost 70.1% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
Owes vs Owns
0.66×Enanta Pharmaceuticals, Inc. owes $0.66 for every $1 it owns (moderate), higher than 69% of Healthcare companies in United States.
Dividend yield
NoneEnanta Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
-3%Revenue fell 3% in the year to Sep 2025, and shrank 9% a year on average over 3 years.
Profit growth
LossEnanta Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-125.4%Enanta Pharmaceuticals, Inc. lost $125 for every $100 of revenue.
Interest cover
Not coveredEnanta Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Sep 2025.
Cash vs debt
Net cashEnanta Pharmaceuticals, Inc. held $131 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Enanta Pharmaceuticals, Inc.: $338 M ÷ $101 M (30 Jun 2026) = 3.3.
What is Enanta Pharmaceuticals, Inc.'s return on equity?
Enanta Pharmaceuticals, Inc. lost 70.1% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
How much does Enanta Pharmaceuticals, Inc. owe compared with what it owns?
Enanta Pharmaceuticals, Inc. owes $0.66 for every $1 it owns (moderate), higher than 69% of Healthcare companies in United States.
Does Enanta Pharmaceuticals, Inc. pay a dividend?
No. Enanta Pharmaceuticals, Inc. does not currently pay a dividend.
Is Enanta Pharmaceuticals, Inc.'s revenue growing?
Revenue fell 3% in the year to Sep 2025, and shrank 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.